WO2024064714A3 - Anticorps qui se lient à cd228 - Google Patents

Anticorps qui se lient à cd228 Download PDF

Info

Publication number
WO2024064714A3
WO2024064714A3 PCT/US2023/074630 US2023074630W WO2024064714A3 WO 2024064714 A3 WO2024064714 A3 WO 2024064714A3 US 2023074630 W US2023074630 W US 2023074630W WO 2024064714 A3 WO2024064714 A3 WO 2024064714A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
antigen
binding fragments
present disclosure
bind
Prior art date
Application number
PCT/US2023/074630
Other languages
English (en)
Other versions
WO2024064714A2 (fr
Inventor
Ryan Heiser
Erin SCHERER
Sharsti SANDALL
Original Assignee
Seagen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc. filed Critical Seagen Inc.
Publication of WO2024064714A2 publication Critical patent/WO2024064714A2/fr
Publication of WO2024064714A3 publication Critical patent/WO2024064714A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des anticorps ou des fragments de liaison à l'antigène de ceux-ci spécifiques contre CD228. De tels anticorps ou fragments de liaison à l'antigène peuvent être utilisés dans de nombreuses applications pharmaceutiques, par exemple, en tant qu'agents anticancéreux et/ou modulateurs immunitaires. La présente invention concerne également des procédés de fabrication des anticorps ou des fragments de liaison à l'antigène décrits ici ainsi que des compositions comprenant de tels anticorps ou fragments de liaison à l'antigène. La présente invention concerne en outre des molécules d'acide nucléique codant pour de tels anticorps ou fragments de liaison à l'antigène. De plus, l'invention concerne des utilisations thérapeutiques et/ou diagnostiques de tels anticorps ou fragments de liaison à l'antigène.
PCT/US2023/074630 2022-09-21 2023-09-20 Anticorps qui se lient à cd228 WO2024064714A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263408605P 2022-09-21 2022-09-21
US63/408,605 2022-09-21

Publications (2)

Publication Number Publication Date
WO2024064714A2 WO2024064714A2 (fr) 2024-03-28
WO2024064714A3 true WO2024064714A3 (fr) 2024-05-02

Family

ID=88600500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/074630 WO2024064714A2 (fr) 2022-09-21 2023-09-20 Anticorps qui se lient à cd228

Country Status (2)

Country Link
TW (1) TW202426501A (fr)
WO (1) WO2024064714A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10428156B2 (en) * 2014-09-05 2019-10-01 Abbvie Stemcentrx Llc Anti-MFI2 antibodies and methods of use
WO2020163225A1 (fr) * 2019-02-05 2020-08-13 Seattle Genetics, Inc. Anticorps anti-cd228 et conjugués anticorps-médicament
WO2022031652A1 (fr) * 2020-08-04 2022-02-10 Seagen Inc. Anticorps anti-cd228 et conjugués anticorps-médicament

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0617706B1 (fr) 1991-11-25 2001-10-17 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
JP2000503639A (ja) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー 分枝ヒドラゾンのリンカー類
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
CA2614436C (fr) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Composes de monomethylvaline presentant des modifications de la chaine laterale de phenylalanine au niveau de l'extremite c
WO2007008848A2 (fr) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Composes de monomethylvaline presentant des modifications carboxy phenylalanine a la terminaison c
LT2211904T (lt) 2007-10-19 2016-11-25 Seattle Genetics, Inc. Cd19 surišantys agentai ir jų panaudojimas
PT2931030T (pt) 2012-12-14 2020-08-03 Open Monoclonal Tech Inc Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10428156B2 (en) * 2014-09-05 2019-10-01 Abbvie Stemcentrx Llc Anti-MFI2 antibodies and methods of use
WO2020163225A1 (fr) * 2019-02-05 2020-08-13 Seattle Genetics, Inc. Anticorps anti-cd228 et conjugués anticorps-médicament
WO2022031652A1 (fr) * 2020-08-04 2022-02-10 Seagen Inc. Anticorps anti-cd228 et conjugués anticorps-médicament

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KLUSSMAN K ET AL: "SECONDARY MAB-VCMMAE CONJUGATES ARE HIGHLY SENSITIVE REPORTERS OF ANTIBODY INTERNALIZATION VIA THE LYSOSOME PATHWAY", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 15, no. 4, 1 July 2004 (2004-07-01), pages 765 - 773, XP001236862, ISSN: 1043-1802, DOI: 10.1021/BC049969T *
L. M. SMITH: "Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97", MOLECULAR CANCER THERAPEUTICS, vol. 5, no. 6, 1 June 2006 (2006-06-01), pages 1474 - 1482, XP055214665, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-06-0026 *
SANDALL SHARSTI L. ET AL: "Abstract 2688: SGN-CD228A: A novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors", CANCER RESEARCH, 1 July 2019 (2019-07-01), XP055861536, Retrieved from the Internet <URL:https://cancerres.aacrjournals.org/content/79/13_Supplement/2688.short> [retrieved on 20211115], DOI: 10.1158/1538-7445.AM2019-2688 *

Also Published As

Publication number Publication date
TW202426501A (zh) 2024-07-01
WO2024064714A2 (fr) 2024-03-28

Similar Documents

Publication Publication Date Title
WO2019224025A3 (fr) Anticorps ayant un effet antagoniste contre cd73
MA49599A1 (fr) Anticorps spécifiques à cd47 et pd-l1
MX2018001567A (es) Novedosos polipeptidos de fusion especificos para lag-3 y pd-1.
PH12021550001A1 (en) Novel fusion protein specific for cd137 and pd-l1
SG10201906859PA (en) Novel proteins specific for angiogenesis
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
MY193112A (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
WO2021064137A3 (fr) Protéines de liaison multi-spécifiques pour le traitement du cancer
WO2021227307A8 (fr) Anticorps anti-cd73 et son utilisation
WO2008060367A3 (fr) Anticorps humains qui se lient au cxcr4, et leurs utilisations
WO2021173896A8 (fr) Matériels et méthodes de modulation d&#39;une réponse immunitaire
MX2019014397A (es) Polipeptidos que enlazan adamts5, mmp13 y agrecano.
MX2022015734A (es) Proteinas de exotoxina a modificadas.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
WO2022051591A3 (fr) Anticorps anti-nectine-4 et leurs utilisations
ZA202201464B (en) Anti-tigit antibodies and application thereof
MX2024005727A (es) Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3.
ZA202304872B (en) Anti-sclerostin constructs and uses thereof
MX2024003355A (es) Anticuerpos anti-cd3.
EP4272822A3 (fr) Immunoglobulines se liant à adamts
WO2024064714A3 (fr) Anticorps qui se lient à cd228
MX2024003615A (es) Anticuerpos que se unen al cumulo de diferenciacion 30 (cd30) y al cumulo de diferenciacion 3 (cd3).
WO2023010065A3 (fr) Compositions et méthodes pour des anticorps anti-pacap
MX2023001158A (es) Anticuerpo especifico para mucina-1 y metodos de uso del mismo.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23798588

Country of ref document: EP

Kind code of ref document: A2